EURI B Stock Overview
European Institute of Science AB (publ) manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
European Institute of Science AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.84 |
| 52 Week High | kr39.00 |
| 52 Week Low | kr3.50 |
| Beta | 1.88 |
| 1 Month Change | -24.71% |
| 3 Month Change | -58.49% |
| 1 Year Change | -87.20% |
| 3 Year Change | -97.37% |
| 5 Year Change | -98.68% |
| Change since IPO | -99.86% |
Recent News & Updates
Shareholder Returns
| EURI B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -19.3% | 2.5% | -0.7% |
| 1Y | -87.2% | -3.4% | 4.4% |
Price Volatility
| EURI B volatility | |
|---|---|
| EURI B Average Weekly Movement | 28.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Volatility Over Time: EURI B's weekly volatility has increased from 24% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 2 | Kirstin Kriz | www.euris.org |
European Institute of Science AB (publ) manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden. It primarily focuses on the diagnostic assays and instrumentation for canine, feline, and equine animals. The company’s products include TurboReader point-of-care instruments that performs measurements using disposable cuvettes; Canine C-Reactive (CRP) TurboReader assays for the quantitative determination of Canine CRP in dog serum or plasma; Feline Hp (Haptoglobin) TurboReader assay for determining Hp in cat serum or plasma; Feline SAA TurboReader assay for the determination of serum amyloid A (SAA) in cat serum or plasma; and Equine SAA TurboReader assay for determining SAA in horse serum or plasma.
European Institute of Science AB (publ) Fundamentals Summary
| EURI B fundamental statistics | |
|---|---|
| Market cap | kr1.33m |
| Earnings (TTM) | -kr2.72m |
| Revenue (TTM) | kr601.00k |
2.2x
P/S Ratio-0.5x
P/E RatioIs EURI B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EURI B income statement (TTM) | |
|---|---|
| Revenue | kr601.00k |
| Cost of Revenue | kr226.00k |
| Gross Profit | kr375.00k |
| Other Expenses | kr3.09m |
| Earnings | -kr2.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -7.83 |
| Gross Margin | 62.40% |
| Net Profit Margin | -452.08% |
| Debt/Equity Ratio | 0% |
How did EURI B perform over the long term?
See historical performance and comparison